It was also proven that calcitriol (1α,25-dihydroxyvitamin D3), as an active vitamin D metabolite, inhibits the tumor-promoting properties of patient-derived CAFs, also modulating many types of immune cells expressing vitamin D receptor (VDR) [177]. This evidence concerns the gene VDR and neoplasm.